Abstract |
A single daily dose of doxazosin taken during a 12-week period produced a significant reduction in blood pressure and left ventricular mass index in patients with mild or moderate hypertension. The systolic shortening coefficient was also increased and a trend in the improvement of ejection fraction, rate of circumferential fiber shortening, systolic contraction time, and preejective/ejective ratio was observed. No change in heart rate was recorded and no patients had side effects. The serum lipid profile was modified favorably, particularly with regard to the low-density lipoprotein cholesterol/ high-density lipoprotein cholesterol ratio. By producing a reduction in blood pressure and left ventricular mass while favorably modifying the serum lipid profile, doxazosin produced a beneficial change in the overall coronary heart disease risk profile.
|
Authors | P Monsalve, O Vera, F Pérez Acuña, O Medina, K Ostojich, B López, N Torres, V Lugo de Franco, R Fonseca |
Journal | American heart journal
(Am Heart J)
Vol. 121
Issue 1 Pt 2
Pg. 356-61
(Jan 1991)
ISSN: 0002-8703 [Print] United States |
PMID | 1824661
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Antihypertensive Agents
- Lipids
- Cholesterol
- Doxazosin
- Prazosin
|
Topics |
- Antihypertensive Agents
(therapeutic use)
- Cardiomegaly
(diagnostic imaging, drug therapy)
- Cholesterol
(blood)
- Coronary Disease
(epidemiology)
- Doxazosin
- Echocardiography
- Female
- Humans
- Hypertension
(drug therapy)
- Lipids
(blood)
- Male
- Middle Aged
- Prazosin
(analogs & derivatives, therapeutic use)
- Risk Factors
- Venezuela
(epidemiology)
|